Exploring Advanced Formulations for Oral Delivery to Enhance Peptide Bioavailability
Time: 3:30 pm
day: Day One
Details:
- First UHT-Compatible Tri-Phase Microcapsule for RTDs: Unveiling a pharma-grade micro-/nano-capsule that co-protects live L. rhamnosus GG, plant proteases, and vitamin B12 through UHT processing and then releases each payload sequentially along the ileum—turning a shelf-stable shake into a precision-delivery system.
- Guideline-Aligned ‘Food-as-Therapy’ for GLP-1 Users: A 30 g ultrafiltered milkprotein matrix, targeted micronutrients (B12, iron, folate, D3), and a ginger/B6 antinausea blend mirror the 2025 GLP-1 nutrition advisory, preserving lean mass and mitigating common drug side-effects.
- De-Risked Bench-to-Clinic & Commercial Pathway: Sharing pilot biomarker data showing increased endogenous GLP-1/PYY and improved satiety; dual IP layers (utility patent + AnaBio license), GRAS-plus ingredient strategy, and a turnkey aseptic line offer partners a clear CMC, regulatory, and co-development route.
